ADMA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against ADMA Biologics for allegedly making false statements regarding revenue growth, engaging in channel stuffing, failing to disclose related party transactions, and lacking adequate internal controls. A short-seller report triggered a 16% stock decline, followed by a 13% drop after a downgrade from Cantor Fitzgerald.